Investment to expand manufacturing and global medicine supply capacity
Marks first international filing for Evofem’s single-dose oral treatment
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This agreement grants Vizient clients enhanced access to Natrelle, the broadest selection of breast implant options on the market
Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease
Takeda will seek an external partner to leverage its cell therapy platform technologies
Repatha is now the first and only PCSK9 inhibitor to demonstrate significant reduction of cardiovascular events as both primary and secondary prevention
Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen is bioequivalent to Victoza Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk
Panacea Biotec receives Rs. 315 crore LoA from UNICEF
Subscribe To Our Newsletter & Stay Updated